

ELECTED HONORS

1998-1999 President, The Endocrine Society

2000 Fellow, American Association for the Advancement of Science

HONORS AND AWARDS

Wilson S. Stone Memorial Award for Research,

University of Texas System, MD Anderson Hospital, Houston, 1976

National Board Award, Medical College of Pennsylvania, 1986

Research Career Development Award, National Cancer Institute, NIH, 1981 - 1986

National Foundation for Cancer Research, Researcher of the Year Award, 1990

NIH MERIT Award, 1992 – 2000

UCHSC Department of Medicine, Basic Research Award, 1992

The Rhone Poulenc Rorer Lecture in honor of William L. McGuire, The Endocrine Society, 1993

The William U. Gardner Memorial Lecture, Yale University School of Medicine, 1993

The University of Helsinki Medal and Second Siltavouri Lecturer, Univ. of Helsinki, Finland, 1993

The President's Guest Lecture; The Society for Gynecologic Investigation, 1994

The University Lecture, Southwestern Medical School, University of Texas at Dallas, 1994

Who's Who in America; Who's Who in the World

The Nobel Assembly, Karolinska Research Lecture, Stockholm, Sweden, 1996

Plenary Lecture, The Israel Endocrine Society, Tel-Aviv, 1997

William L. McGuire Memorial Lecture, San Antonio Breast Cancer Symposium, 1997

Plenary Lecture, The Australian Society for Medical Research, Adelaide, 1997

The Bicentennial Lecture, University of Louisville, Kentucky, 1998

Distinguished Scientist Award, The Clinical Ligand Binding Assay Society, 2000

Serono Endowed Lectureship, American Society for Reproductive Medicine, San Diego, 2000

Anita K. Payne Lectureship, University of Michigan, Ann Arbor, 2000

Novum Lecturer, Karolinska Institute, Sweden, 2001

Thomas G. Muldoon Memorial Lecture, Medical College of Georgia, 2001

The Robert W. Schrier Award for Excellence, University of Colorado, 2002

President's Lecture, Society for the Study of Reproduction, 2002

CD Christian Lecture, Society for Gynecological Investigation, 2003

Distinguished Professor, Board of Regents, University of Colorado, 2004

Keynote Lecture, Endometrial Biology – Science meets Clinical Practice, San Francisco, 2006

The Play for P.I.N.K. Award, Breast Cancer Research Foundation, October 2006

NIEHS Distinguished Lecture, NIH, Research Triangle Park, NC, March 2008

The Year in Hormones and Cancer Lecture, The Endocrine Society, June 2008

MEETINGS ORGANIZER

Keystone Symposium: Steroid/Thyroid/Retinoic Acid Receptor Family, 1996

Keystone Symposium: Nuclear Receptor Gene Family, 1998

Estrogen & Progesterone: Receptors and Ligands in the Next Millenium,
Society for Gynecological Investigation, 1999
Keystone Symposium: Nuclear Receptors, 2000
Satellite Symposium on Hormone Dependent Cancers
International Congress of Endocrinology, Australia, 2000
International Congress on Hormonal Steroids & Hormones and Cancer, Fukuoka,
Japan, 2002
Effects of Estrogen Deprivation, Half Moon Bay, CA, July 2002; July 2003
International Congress of Endocrinology, Fukuoka, Japan 2002; Athens, Greece, 2006

SOCIETY MEMBERSHIPS

American Federation for Clinical Research
The Endocrine Society
American Association for Cancer Research
Western Society for Clinical Investigation
The American Society for Cell Biology
American Society for Biochemistry and Molecular Biology
American Association for the Advancement of Science

CURRENT EDITORIAL BOARDS

Editorial Board, BREAST CANCER RESEARCH AND TREATMENT, 1980-present
Corresponding Editor, THE JOURNAL OF STEROID BIOCHEMISTRY, 1986-present
Editorial Board, ENDOCRINE RELATED CANCER, 1994-present
Editorial Academy, INTERNATIONAL JOURNAL OF ONCOLOGY, 1994-present
Associate Editor, REPRODUCTIVE MEDICINE REVIEW, 1994-present
Editorial Board, J. OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1995-present
Editorial Board, PHYSIOLOGICAL REVIEWS, 2004-2008
Associate Editor, Endocrinology, ANNUAL REVIEWS OF PHYSIOLOGY, 2004-2006
Associate Editor for Endocrinology, BREAST CANCER RESEARCH, 2005-

SELECTED EXTRAMURAL COMMITTEES

The Endocrine Society

Program Committee, 1988-1990
Elected; Nominating Committee, 1989-1991; 2000-2001
Chair, 1990
Council, 1992-1995
Vice-Chair, Research Affairs Subcommittee
Publications and Journals Steering Committees
Executive Committee, 1997-2000
Elected; President-Elect, 1997-1998
President, 1998-1999
Past President, 1999-2000
Advisory Board, The Hormone Foundation, 1999-2004
Women in Endocrinology, Awards Committee, 2001
Chair, 2002
Awards Committee, 2003-2007

Chair 2007

Federation of American Societies for Experimental Biology

Board of Directors, 2002-2004

Finance Committee, 2002-2004

American Association for Cancer Research

Program Committee, 1994-1995

State Legislative Committee, 1994-2000

Chair, Awards Committee, AACR-NFCR Professorship in Basic Cancer Research, 2000

National Science Foundation

Cellular Physiology Study Section, 1985-1988

National Institutes of Health

Biochemical Endocrinology Study Section, 1989-1993

Reviewers Reserve, 1993-1997

Member, IRG Scientific Review Panel, Endocrinology, Metabolism & Reproductive Sciences, 2000

The President's Cancer Panel

Special Commission on Breast Cancer, NCI, 1992-1993

The International Society for Endocrinology

Program Committee, 1994-1996

Member, Central Committee 2000-2008

The International Congress on Hormonal Steroids

International Organizing Committee, 1997-present

Department of Defense

Breast Cancer Research Program, Programmatic Review Committee, 2005; 2006

SELECTED INTRAMURAL COMMITTEES (see appendix)

Secretary of the Executive Faculty, University of Colorado School of Medicine

Member, Executive Committee, 1983-1984, 1985-1986

Member, Faculty Senate, 1983-1984; 1985-1986; 1988-1990

Department of Medicine Faculty Promotions Committee (Assistant - Associate), 1984-1999

Medical School Admissions Committee, 1986-1991

Medical Scientist Training Program, 1987-1992

Steering Committee, 1987-1992

Admissions Committee, 1987-1992

Molecular Biology Program – Graduate Faculty; 1988-2007

Space Selection Committee, 1988-1989

Curriculum Committee, 1988-1990

Admissions Committee, 1989-1995

Director: Molecular Biology PhD Program for Clinical Fellows, 1993-present
Reproductive Sciences Program – Graduate Faculty
Cancer Biology Program – Graduate Faculty
Chancellor's Committee, Indirect Cost Recovery, 1989-1990
School of Medicine Standing Committee on Research Ethics, 1989-2000
Fiscal Oversight Committee, School of Medicine, 1990-1991
Chair, Physiology Department Chair Search Committee, 1992-1993
University of Colorado Cancer Center
Program Director: Hormones and Cancer Program, 1994-1998
HHMI Faculty Research Awards Review Committee, 2002
Research Infrastructure Committee, 2002
Department of Medicine, Finance Committee, 2003
Department of Medicine, Post-Tenure Review Committee, 2003 – present
University of Colorado System, Privilege & Tenure Committee, 2006 – present
University of Colorado System, Distinguished Professors Committee, 2006 – present

COMMUNITY SERVICE

Cancer League of Colorado
Scientific Advisory Board, 1986-1990
Chair, 1988-1990
Arizona Cancer Center
Scientific Advisory Board, 2000-2004
The Avon Foundation
Research Programs & Underserved Minorities Mammography, Outreach
& Breast Cancer Survivorship Programs
Program Director, 2001-present

PATENT

Progesterone Receptor-Regulated Gene Expression and Methods Related Thereto.
UTC Ref 10091H

OTHER ACTIVITIES AND FUNDING

See Appendix.

PUBLICATIONS

REFEREED JOURNAL ARTICLES

1. Green I and **(Horwitz) Bloch K**. Uptake of particulate matter within the thymus of adult and newborn mice. NATURE 200:1099-1101, 1963.
2. **Horwitz KB**, Ball RJ and Schmidt JP. Resistance to infection of mice and hamsters following short-term acceleration stress. AEROSPACE MEDICINE 41:1248-1251, 1971.
3. **Horwitz KB**, and McGuire WL. Specific progesterone receptors in human breast cancer. STEROIDS 25:497-505, 1975.
4. **Horwitz KB**, McGuire WL, Pearson OH and Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis [on role of progesterone receptors]. SCIENCE 189:726-727, 1975.
5. **Horwitz KB**, Costlow ME and McGuire WL. MCF-7: A human breast cancer cell line with estrogen, androgen, progesterone and glucocorticoid receptors. STEROIDS 26:785-795, 1975.
6. McGuire WL, **Horwitz KB**, and Chamness GC. A physiological role for estrogen and progesterone in breast cancer. J STEROID BIOCHEM 7:875-882, 1976.
7. **Horwitz KB** and McGuire WL. Progesterone and progesterone receptors in experimental breast cancer. CANCER RESEARCH 37:1733-1738, 1977.
8. Zava DT, Chamness GC, **Horwitz KB** and McGuire WL. Human breast cancer: biologically active estrogen receptor in the absence of estrogen? SCIENCE 196:663-664, 1977.
9. McGuire WL, **Horwitz KB**, Pearson OH and Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. CANCER 39:2934-2947, 1977.
10. **Horwitz KB** and McGuire WL. Estrogen control of progesterone receptor in human breast cancer: correlation with nuclear processing of estrogen receptor. J BIOL CHEM 253:2223-2228, 1978.
11. McGuire WL, Zava DT, **Horwitz KB**, Garola RE and Chamness GC. Receptors and breast cancer: do we know it all? J STEROID BIOCHEM 9:461-466, 1978.
12. **Horwitz KB**, Koseki Y and McGuire WL. Estrogen control of progesterone receptors in human breast cancer: role of estradiol and antiestrogen. ENDOCRINOLOGY 103:1742-1751, 1978.

13. **Horwitz KB** and McGuire WL. Nuclear mechanisms of estrogen action: effects of estradiol and antiestrogen on cytoplasmic and nuclear estrogen receptors and nuclear receptor processing. J BIOL CHEM 253:8185-8191, 1978.
14. **Horwitz KB**, Zava DT, Jensen EM and McGuire WL. Human breast cancer cell lines: steroid receptor analyses. CANCER RESEARCH 38:2434-2437, 1978.
15. Zava DT, Landrum B, **Horwitz KB** and McGuire WL. Measurement of androgen receptor with [3H]methyltrienolone in systems containing both androgen and progesterone receptors. ENDOCRINOLOGY 104:1007-1012, 1979.
16. Martin PM, **Horwitz KB**, Ryan DS and McGuire WL. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. ENDOCRINOLOGY 103:1860-1867, 1978.
17. **Horwitz KB** and McGuire WL. Actinomycin D prevents nuclear processing [ligand dependent downregulation] of estrogen receptors. J BIOL CHEM 253:6315-6318, 1978.
18. **Horwitz KB** and McGuire WL. Estrogen control of progesterone receptor induction in human breast cancer: Role of nuclear estrogen receptors. ADV EXP BIOL MED 117:95-110, 1979.
19. **Horwitz KB** and McGuire WL. Studies on mechanisms of estrogen and antiestrogen action in human breast cancer. RECENT RESULTS IN CANCER RESEARCH 71:45-58, 1980.
20. Edwards DP, Martin PM, **Horwitz KB** Chamness GC and McGuire WL. Estrogen receptors in human breast cancer: Subcellular compartmentalization of unfilled sites. EXPERIMENTAL CELL RES 127:197-213, 1980.
21. **Horwitz KB** and McGuire WL. Nuclear estrogen receptors: Effects of inhibitors on processing and steady state levels. J BIOL CHEM 255:9699-9705, 1980.
22. **Horwitz KB**, Aiginger P, Kutten F and McGuire WL. Nuclear estrogen receptor release from antiestrogen suppression: amplified induction of progesterone receptor. ENDOCRINOLOGY 108:1703-1709, 1981.
23. **Horwitz KB**. Is a functional estrogen receptor always required for progesterone receptor induction in breast cancer? J STER BIOCHEM 15:209-217, 1981.
24. **Horwitz KB** and Horwitz LD. Cardiovascular tissues are targets for estrogen, androgen, glucocorticoid and progestin action. J CLIN INVEST 69:750-758, 1982.

25. **Horwitz KB**, Mockus MB and Lessey BA. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. *CELL* 28:633-642, 1982.
26. Mockus MB, Lessey BA, Bower MA and **Horwitz KB**. Estrogen insensitive progesterone receptors in a human breast cancer cell line: Characterization of receptors and of a ligand exchange assay. *ENDOCRINOLOGY* 110:1564-1571, 1982.
27. Lessey BA, Alexander PS and **Horwitz KB**. The subunit structure of human breast cancer progesterone receptors: Characterization by chromatography and photoaffinity labeling. *ENDOCRINOLOGY* 112:1267-1274, 1983.
28. Mockus MB and **Horwitz KB**. Progesterone receptors in human breast cancer: Stoichiometric translocation and nuclear receptor processing. *J BIOL CHEM* 258:4778-4783, 1983.
29. **Horwitz KB**, Mockus MB, Pike AW, Fennessey PV and Sheridan RL. Progesterone receptor replenishment in T47D human breast cancer cells: Roles of protein synthesis and hormone metabolism. *J BIOL CHEM* 258:7603-7610, 1983.
30. **Horwitz KB** and Alexander PS. In situ photolinked nuclear progesterone receptors of human breast cancer: subunit molecular weights after transformation and translocation. *ENDOCRINOLOGY* 113:2195-2201, 1983.
31. Sedlacek SM and **Horwitz KB**. The role of progestins and progesterone receptors in the treatment of breast cancer. *STEROIDS* 44:467-484, 1984.
32. **Horwitz KB** and Freidenberg GR. Progestins inhibit growth and increase insulin receptors in antiestrogen resistant T47Dco human breast cancer cells: implications for endocrine therapies. *CANCER RESEARCH* 45:167-173, 1985.
33. **Horwitz KB**. The antiprogestin RU38 486: Receptor mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells. *ENDOCRINOLOGY* 116:2236-2245, 1985.
34. Hiatt WR, Travis VL, **Horwitz KB** and Horwitz LD. The effect of platelet protein and DNA on the measurement of human lymphocyte beta adrenergic receptor number. *J RECEPTOR RESEARCH* 5:419-429, 1985.
35. **Horwitz KB**, Francis MD and Wei LL. Hormone-dependent covalent modification and processing of human progesterone receptors in the nucleus. *DNA* 4:451-460, 1985.

36. Wei LL and **Horwitz KB**. The structure of progesterone receptors. STEROIDS 24:677-695, 1985.
37. **Horwitz KB**, Wei LL and Francis MD. Structural analyses of progesterone receptors. J STEROID BIOCHEM 24:109-117, 1986.
38. Fennessey PV, Pike AW, Gonzalez-Aller C and **Horwitz KB**. Progesterone metabolism in T47Dco human breast cancer cells. I. 5 α -Pregnan-3 β ,6 α -diol-20-one is the secreted product. J STEROID BIOCHEM 25:641-648, 1986.
39. **Horwitz KB**, Pike AW, Gonzalez-Aller C and Fennessey PV. Progesterone metabolism in T47Dco human breast cancer cells. II. Intracellular metabolic pathway of progesterone and synthetic progestins. J STEROID BIOCHEM 25:911-916, 1986.
40. Law ML, Kao FT, Wei Q, Hartz JA, Green GL, Schulz TZ, Conneely OM, Jones C, Puck TT, O'Malley BW and **Horwitz KB**. The progesterone receptor gene maps to human chromosome band 11q13, site of the mammary oncogene int-2. PROC NATL ACAD SCI, USA 84:2877-2881, 1987.
41. Estes PA, Suba EJ, Lawler-Heavner J, Wei LL, Toft DO, **Horwitz KB** and Edwards DP. Immunologic analysis of human breast cancer progesterone receptors. I. Immunoaffinity purification of transformed receptors and monoclonal antibody production. BIOCHEMISTRY 26:6250-6262, 1987.
42. Wei LL, Sheridan PL, Krett NL, Francis MD, Toft DO, Edwards DP and **Horwitz KB**. Immunologic analysis of human breast cancer progesterone receptors. II. Structural analysis, nuclear phosphorylation and processing. BIOCHEMISTRY 26:6262-6272, 1987.
43. **Horwitz KB**. Purification, monoclonal antibody production and structural analyses of human progesterone receptors. J STEROID BIOCHEM 31:573-578, 1988.
44. Wei LL, Krett NL, Francis MD, Gordon DF, Wood WM, O'Malley BW and **Horwitz KB**. Multiple human progesterone receptor messenger RNAs and their autoregulation by progestin agonists and antagonists in human breast cancer cells. MOLEC ENDOCRINOLOGY 2:62-72, 1988.
45. Sheridan PL, Krett NL, Gordon JA and **Horwitz KB**. Down-regulation of human progesterone receptors is independent of their nuclear phosphorylation. MOLEC ENDOCRINOLOGY 2:1329-1342, 1988.
46. Krett NL, Wei LL, Francis M, Nordeen SK, Gordon DF, Wood WM and **Horwitz KB**. Human progesterone A-receptors can be synthesized intracellularly and are

- biologically functional. *BIOCHEM BIOPHYS RES COMMUNIC* 157:278-285, 1988.
47. Sheridan PL, Evans RM and **Horwitz KB**. Phosphotryptic peptide analysis of human progesterone receptors: New phosphorylated sites formed in nuclei after hormone treatment. *J BIOL CHEM* 264(11):6520-6528, 1989.
 48. Sheridan PL, Francis MD and **Horwitz KB**. Synthesis of human progesterone receptors in T47D cells: Nascent A- and B-receptors are active without a phosphorylation-dependent post-translational maturation step. *J BIOL CHEM* 264(12):7054-7058, 1989.
 49. Cappelletti V, Patriarca C, Granata G, Cattoretti G, Coradini D, DiFronzo G and **Horwitz KB**. Progesterone receptor determination in human breast tumors by immunocytochemical and biochemical techniques. *BREAST CANCER RES AND TREATMENT* 14:217-225, 1989.
 50. Graham ML, Bunn PA, Jewett P, Gonzalez-Aller C and **Horwitz KB**. Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: Characterization of an assay in breast cancer cell lines. *CANCER RESEARCH* 49:3934-3942, 1989.
 51. Graham ML, Lundquist K and **Horwitz KB**. Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: Analysis of breast cancer cell mixtures and genetic instability of the T47D line. *CANCER RESEARCH* 49:3943-3949, 1989.
 52. **Horwitz KB**, Sheridan PL, Wei LL and Krett NL. Human progesterone receptors: Synthesis, structure, and phosphorylation. *PROG CLIN BIOL RES* 322:41-52, 1990.
 53. Graham ML, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL and **Horwitz KB**. Genetic instability and estrogen receptor mutations: Possible elements in the progression of breast cancers to hormone resistance. *CANCER RESEARCH* 50:6208-6217, 1990.
 54. Kastner P, Bocquel MT, Turcotte B, Garnier J-M, **Horwitz KB**, Chambon P and Gronemeyer H. Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms. *J BIOL CHEM* 265:12163-12167, 1990.
 55. Wei LL, Gonzalez-Aller C, Wood WM and **Horwitz KB**. 5'-heterogeneity in human progesterone receptor transcripts predicts a new amino-terminal truncated "C"-receptor and unique A-receptor messages. *MOLEC ENDOCRINOLOGY* 4:1833-1840, 1990.

56. Takimoto GS, Tasset DM, Miller LA and **Horwitz KB**. Epitope mapping of the anti-human progesterone receptor monoclonal antibody, AB-52. *J STER BIOCHEM AND MOLEC BIOL*, 39:687-692, 1991.
57. Graham ML, Smith JA, Jewett PB and **Horwitz KB**. Heterogeneity of progesterone receptor content and remodeling by tamoxifen, characterize subpopulations of cultured human breast cancer cells: Analysis by quantitative dual parameter flow cytometry. *CANCER RESEARCH*, 52:593-602, 1992.
58. Takimoto GS, Tasset DM, Eppert EC and **Horwitz KB**. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages. Analysis with zinc finger mutants and the progesterone antagonist ZK98299. *PROC NATL ACAD SCI USA*, 89:3050-3054, 1992.
59. Leslie KK, Tasset DM and **Horwitz KB**. Functional analysis of a mutant estrogen receptor isolated from T47D_{CO} breast cancer cells. *AMER J OBSTET GYNEC*, 166:1053-1061, 1992.
60. **Horwitz KB**. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? *ENDOCRINE REVIEWS*, 13:146-163, 1992.
61. Takimoto GS and **Horwitz KB**. Progesterone receptor phosphorylation. Complexities in defining a functional role. *TRENDS IN ENDOCRINOLOGY AND METAB*, 4:1-7, 1993.
62. Sartorius CA, Tung L, Takimoto GS and **Horwitz KB**. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP, *J BIOL CHEM*, 5:9262-9266, 1993.
63. **Horwitz KB**. Mechanisms of hormone resistance in breast cancer. *BREAST CANCER RES AND TREATMENT*, 26:119-130, 1993.
64. Tung L, Mohamed KM, Hoeffler JP, Takimoto GS, and **Horwitz KB**. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements, and are dominantly inhibited by A-receptors. *MOLECULAR ENDOCRINOLOGY*, 7:1256-1265, 1993.
65. Crowley ST, Demsey EC, **Horwitz KB** and Horwitz LD. Platelet-induced smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. *CIRCULATION* 90:1908-1918, 1994.
66. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS and **Horwitz KB**. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only B-receptors are switched to transcriptional

- agonists by antiprogestins plus cAMP. *CANCER RESEARCH*, 54:3868-3877, 1994.
67. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS and **Horwitz KB**. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. *MOLEC ENDOCRINOL*, 8:1347-1360, 1994.
 68. Mohamed KM, Tung L, Takimoto GS and **Horwitz KB**. The leucine zippers of c-Fos and c-Jun for progesterone receptor dimerization. A-dominance in the A/B heterodimer. *J STER BIOCHEM MOLEC BIOL*, 51:241-250, 1994.
 69. **Horwitz KB**. Editorial: When tamoxifen turns bad. *ENDOCRINOLOGY* 136:821-823, 1995.
 70. Takimoto GS, Hovland AR, Tasset DM, Melville MY, Tung L and **Horwitz KB**. Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. *J BIOL CHEM* 271:13308-13316, 1996.
 71. **Horwitz KB**, Jackson TA, Bain DL, Richer JK, Takimoto GS and Tung L. Nuclear receptor coactivators and corepressors. *MOLEC ENDOCRINOL* 10:1167-1177 1996.
 72. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L and **Horwitz KB**. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge-domain binding coactivator, L7/SPA and the corepressors N-CoR or SMRT. *MOLEC ENDOCRINOL* 11:693-705, 1997.
 73. Petz LN, Nardulli AM, Kim J, **Horwitz KB**, Freedman LP, and Shapiro DJ. DNA bending is induced by binding of the glucocorticoid receptor DNA binding domain and progesterone receptors to their response element. *J STEROID BICHEM MOLEC BIOL* 60:31-41, 1997.
 74. Miller MM, James RA, Richer JK, Gordon DF, Wood WM and **Horwitz KB**. Progesterone regulated expression of flavin-containing monooxygenase 5 is controlled by the B-isoform of progesterone receptors: Implications for tamoxifen carcinogenicity. *J CLIN ENDOCRINOL METAB* 82:2956-2961, 1997.
 75. Groshong SD, Owen GI, Grimison B, Schauer IE, Daly MC, Langan TA, Sclafani RA, Lang CA and **Horwitz KB**. Biphasic regulation of breast cancer cell growth by progesterone: Role of the cdk inhibitors p21 and p27^{Kip1}. *MOLEC ENDOCRINOL* 11:1593-1607, 1997.
 76. Richer JK, Lange-Carter C, Wierman AM, Brooks KM, Jackson TA, Tung L, Takimoto GS and **Horwitz KB**. Novel progesterone receptor variants in breast

- cancers and normal breast cells repress transcription by wild-type receptors. BREAST CANCER RES AND TREAT 48:231-241, 1998.
77. Hovland AR, Powell RL, Takimoto GS, Tung L and **Horwitz KB**. An N-terminal inhibitory function (IF) suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. J BIOL CHEM, 273:5455-5460, 1998.
 78. Owen GI, Richer JK, Tung L, Takimoto GS, and **Horwitz KB**. Progesterone regulates transcription of the p21^{WAF1} cyclin dependent kinase inhibitor gene through Sp1 and CBP/p300. J BIOL CHEM 273:10696-10701, 1998.
 79. Kumar NS, Richer JK, Owen GI, Litman E, **Horwitz KB** and Leslie KK. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: Implications for unopposed estrogen action. CANCER RESEARCH 58: 1860-1865, 1998.
 80. Pahl PMB, Hodges-Garcia YK, McItesen L, Perryman MB, **Horwitz KB** and Horwitz LD. ZNF207, A novel zinc finger gene on chromosome 6p21.3. GENOMICS 53: 410-412, 1998.
 81. Lange CA, Richer JK, Shen T and **Horwitz KB**. Convergence of Progesterone and Epidermal Growth Factor Signaling in Breast Cancer. Potentiation of Mitogen-Activated Protein Kinase Pathways. J BIOL CHEM. 273: 31308-31316, 1998.
 82. Richer JK, Lange CA, Manning NG, Owen GI, Powell R and **Horwitz KB**. Convergence of Progesterone with Growth Factor and Cytokine Signaling in Breast Cancer. Progesterone Receptors regulate Stat5 expression and activity. J BIOL CHEM. 273: 31317-31326, 1998.
 83. Nagaya T, Chen K-S, Fujieda M, Ohmori S, Richer JK, **Horwitz KB**, Lupski JR and Seo H. Localization of the human nuclear receptor corepressor (hN-CoR) gene between the CMT1A and SMS critical regions of chromosome 17p11.2. GENOMICS 59:339-341, 1999.
 84. Takimoto GS, Graham JD, Jackson TA, Tung L, Powell R, Horwitz LD and **Horwitz KB**. Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J STEROID BIOCHEM & MOLEC BIOL, 69: 45-50, 1999.
 85. Hodges-Garcia YK, Richer JK, **Horwitz KB** and Horwitz LD. Variant Estrogen and Progesterone Receptor messages are expressed in vascular smooth muscle. CIRCULATION, 99: 2688-2693, 1999.

86. Lange CA, Richer JK and **Horwitz KB**. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. *MOLECULAR ENDOCRINOLOGY* 13: 829-836, 1999.
87. **Horwitz, KB**. Bringing estrogen receptors under control. *BREAST CANCER RESEARCH* 1: 5-7, 1999.
88. Hodges-Garcia YK, Tung L, Yan X-D, Graham JD, **Horwitz KB** and Horwitz LD. Estrogen Receptor α and β : Prevalence of Estrogen Receptor β mRNA in human vascular smooth muscle and transcriptional effects. *CIRCULATION* 101: 1792-1798, 2000.
89. Sartorius CA, Takimoto GS, Richer JK, Tung L and **Horwitz KB**. Association of the Ku autoantigen/DNA-dependent protein kinase holoenzyme and poly (ADP-ribose) polymerase with the DNA binding domain of progesterone receptors. *J. MOLECULAR ENDOCRINOLOGY*, 24: 165-182, 2000.
90. Lange CA, Shen T and **Horwitz KB**. Phosphorylation of human progesterone receptors at serine 294 by mitogen activated protein kinase signals their degradation by the 26S proteasome. *PROC NATL ACAD SCI (USA)*, 97(3):1032-1037, 2000
91. Bain DL, Franden MA, McManaman JL, Takimoto GS and **Horwitz KB**. The N-terminal region of the human progesterone A-receptor: Structural analysis and the influence of the DNA binding domain. *J BIOL CHEM*, 275 (10): 7313-7320, 2000.
92. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L and **Horwitz KB**. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. *STEROIDS*, 65 (10/11): 579-584, 2000.
93. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L and **Horwitz KB**. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? *J STEROID BIOCH & MOL BIOL*, 74 (5): 255-259, 2000.
94. Kinyamu HK, Fryer CJ, **Horwitz KB** and Archer TK. The mouse mammary tumor virus promoter adopts distinct chromatin structures in human breast cancer cells with and without glucocorticoid receptor. *J BIOL CHEM*, 275 (26): 20061-20068, 2000.
95. Shen T, **Horwitz KB** and Lange CA. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of Serine 294. *MOLEC CELL BIOL*. 21(18): 6122-6131, 2001

96. Bain DL, Franden MA, McManaman JL, Takimoto GS and **Horwitz KB**. The N-terminal region of human progesterone B-receptors. Biochemical and biophysical comparison to A-receptors. J BIOL CHEM, 276 (26): 23825-23831, 2001
97. Pahl PMB, Horwitz MA, **Horwitz KB** and Horwitz LD. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. BREAST CANCER RES & TREAT, 69:69-79, 2001.
98. Tung L, Shen T, Abel MG, Powell RL, Takimoto GS, Sartorius CA and **Horwitz KB**. Mapping the unique activation function 3 in the progesterone B-receptor upstream segment. Two LXXLL motifs and a tryptophan residue are required for activity. J BIOL CHEM, 276 (43): 39843-39851, 2001.
99. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM and **Horwitz KB**. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J BIOL CHEM, 277 (7), 5209-5218, 2002.
100. Jacobsen BM, Schittone S, Richer JK and **Horwitz KB**. Construction of new breast cancer cell lines with inducible progesterone A- and B-receptors: Ligand independent effects and isoform ratios. J BIOL CHEM, 277 (31): 27793-27800, 2002.
101. Abdel-Hafiz H, Takimoto GS and **Horwitz KB**. The inhibitory function (IF) in human progesterone receptor N-termini binds small ubiquitin-like modifier (SUMO-1) protein to regulate autoinhibition and transrepression. J. BIOL. CHEM. 277 (37): 33950-33956, 2002.
102. Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL and **Horwitz KB**. Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. J STER BIOCH & MOL BIOL, 85: 209-219, 2003
103. Qiu M, Olsen A, Faivre E, **Horwitz KB** and Lange CA. Mitogen Activated Protein Kinase regulates nuclear association of human progesterone receptors. MOLECULAR ENDOCRINOLOGY, 17(4): 628-642, 2003.
104. Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL and **Horwitz KB**. Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. J STER BIOCH & MOL BIOL, 85: 209-219, 2003
105. Jacobsen BM, Richer JK, Sartorius CA and **Horwitz KB**. Expression profiling of human breast cancers, and gene regulation by progesterone receptors. J OF MAMMARY GLAND BIOLOGY & NEOPLASIA, 8:257:268, 2003

106. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, **Horwitz KB** and Fuqua Breast cancer patients with Progesterone Receptor-A rich tumors have poorer disease-free survival. *CLINICAL CANCER RESEARCH*, 10:2751-2760, 2004
107. Wu J, Richer JK, **Horwitz KB** and Hyder M. Progesterin-dependent induction of VEGF in human breast cancer cells: preferential regulation by progesterone receptor-B. *CANCER RESEARCH*, 64(6):2238-44, 2004
108. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, Villalon M, Brosens JJ, White JO, Richer JK, **Horwitz KB** and Owen GI. Progesterone increases Tissue Factor gene expression, procoagulant activity and invasion in the breast cancer cell line ZR-75-1. *JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM*, 90(2):1181-1188, 2005.
109. Jacobsen BM, Richer JK, Schittone S and **Horwitz KB**. Progesterone independent effects of progesterone receptors (PR) in estrogen receptor positive breast cancer: PR isoform-specific gene regulation and tumor biology. *MOLECULAR ENDOCRINOLOGY*, 19(3): 574-587, 2005
110. Fuqua SAW, Cui Y, Lee AV, Osborne CK and **Horwitz KB**. Response to: "Time to Stop Progesterone Receptor Testing in Breast Cancer Management. Olivoto et al. *JCO* 22(2004):1769". *JOURNAL OF CLINICAL ONCOLOGY*, 23(4): 931-932, 2005
111. Carvajal A, Espinoza N, Kato S, Pinto M, Sadarangani A, Monso C, Aranda E, Villalon M, Richer JK, **Horwitz KB**, Brosens JJ and Owen GI. Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75. *BREAST CANCER RESEARCH & TREATMENT*, in press, 2005.
112. Ghatge R, Jacobsen BM, Schittone S, **Horwitz KB**. Medroxyprogesterone acetate in breast cancer cells: Gene regulatory overlap with dihydrotestosterone in breast cancer cells. *BREAST CANCER RESEARCH*, 7:R1036-R1050, 2005
113. Sartorius CA, Harvell DME, Shen T and **Horwitz KB**. Progestins initiate a luminal to myoepithelial switch in estrogen dependent human breast tumors without altering growth. *CANCER RESEARCH*, 65 (21): 9779-9788, November, 2005
114. Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winnecker RC, **Horwitz KB** and Lyttle CR. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. *J STEROID BIOCHEM MOL BIO*, 97(4): 328-341, 2005.

115. Harvell DME, Richer JK, Allred DC, Sartorius CA and **Horwitz KB**. Estradiol regulates different genes in human breast tumor xenografts compared to identical cultured cells. *ENDOCRINOLOGY*, 147: 700-713, 2006
116. Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Garcia MV and **Horwitz KB**. Spontaneous fusion with and transformation of mouse stroma by malignant human breast cancer epithelium; *CANCER RESEARCH*, 66 (26): 8274 – 8279, 2006
117. Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer S, Broaddus RR, **Horwitz KB** and Richer JK. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. *CANCER RESEARCH*, 66(7): 3893-3902, 2006
118. Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, **Horwitz KB**, Lam EWF, Brosens JJ. Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone, *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES*, 103(44): 16272-16277, 2006
119. Tung L, Abdel-Hafiz H, Shen T, Harvell DME, Nitao LK, Richer JK, Sartorius SA, Takimoto GS, and **Horwitz KB**. Progesterone receptors (PR)-B and PR-A regulated transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. *MOLECULAR ENDOCRINOLOGY*, 20(11): 2656-2670, 2006
120. Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA and **Horwitz KB**. A new model of estrogen receptor positive, estrogen dependent breast cancer metastasis: Altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. *CANCER RESEARCH*, 66 (18) 9308-9315, 2006
121. Byron SA, **Horwitz KB**, Richer JK, Lange CA, Zhang X and Yee D. Insulin receptor substrates mediate distinct biological responses to IGF-IR activation in breast cancer cells. *BRITISH JOURNAL OF CANCER*, 95: 1220-1228, 2006
122. Chadli A, Graham JD, Abel MG, Jackson TA, Gordon DF, Wood WM, Felts SJ, **Horwitz KB** and Toft DO. GC UNC-45 is a novel regulator for the progesterone receptor/hsp 90 chaperoning pathway. *MOLECULAR & CELL BIOLOGY*, 26(5): 1722-1730, 2006
123. Harrell JC, Dye WW, Harvell DME, Pinto M, Jedlicka P, Sartorius CA and **Horwitz KB**. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. *CANCER RESEARCH*, 67(21): 10582-10591, 2007
124. Harrell JC, Sartorius CA, Dye WW, Jacobsen BM and **Horwitz KB**. ZsGreen labeling of breast cancer cells to visualize metastasis. *CLONTECHNIQUES XXII*, No 2. 23-25, 2007

125. Harvell DME, Spoelstra NS, Singh M, Finlayson C, Phang T, Hunter L, Dye WW, Borges VB, Elias AD, **Horwitz KB** and Richer JK. Molecular signatures of response to neoadjuvant endocrine therapy for breast cancer. *BREAST CANCER RESEARCH & TREATMENT*, in press, 2008
126. Harvell DME, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VB, Elias AD and **Horwitz KB**. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: Tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. *BREAST CANCER RESEARCH & TREATMENT*, in press, 2008
127. Harrell JC, Dye WW, Harvell DME, Sartorius CA and **Horwitz KB**. Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: A comparison of experimental breast cancers and their lymph node metastases. *CLINICAL AND EXPERIMENTAL METASTASIS*, 25:81-88, 2008
128. Singh M, Spoelstra NS, Howe JA, Torkko KC, Clark HR, Darling DS, Shroyer KK, **Horwitz KB**, Broaddus RR and Richer JK. ZEB1 expression in Type I vs. Type II endometrial cancers: a marker of aggressive disease. *MODERN PATHOLOGY*, 21: 912-923, 2008.
129. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Harrell JC, **Horwitz KB**, Billheimer D, Heichman K, Welm A, Schiemann WP and Ford HL. The Six1 homeoprotein induces Transforming Growth Factor- β signaling, epithelial to mesenchymal transition, and breast cancer metastasis, Submitted, 2008
130. **Horwitz KB**, Dye WW, Kabos P, Harrell JC and Sartorius CA. Rare steroid receptor negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts, *PROCEEDINGS NATIONAL ACADEMY OF SCIENCES*, 105(15): 5774-5779, 2008
131. **Horwitz KB** and Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in pre-existing breast cancers: A hypothesis. Commentary: *JOURNAL CLINICAL ENDOCRINOLOGY AND METABOLISM*, 93 (9): 3295-3298, 2008
132. Spillman MA, Sartorius CA, Harrell JC, Manning NG, Jacobsen BM and **Horwitz KB**. Estrogen enhances tumor growth and metastases in human ovarian cancer nude mouse xenograft models. *AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY*, Submitted, 2008. Hunter Prize Thesis Award, American Gynecological & Obstetrics Society
133. **Horwitz KB**. Update of estrogen plus progestin therapy for menopausal hormone replacement and an explanation for the associated increased risk of breast cancer. *MOLECULAR ENDOCRINOLOGY*, in press 2008. The Year in Hormones and Cancer Lecture, ENDO '08.

BOOKS

Horwitz KB. Endocrine Aspects of Cancer (Vol. 1), Negro-Vilar A and Horwitz KB (Editors), ENDOCRINE REVIEWS MONOGRAPHS. The Endocrine Society Press, Bethesda, MD, 1993

Horwitz KB and Clarke C. (Editors). Estrogens and Progestins in Mammary Gland Development and Neoplasia IN: J MAMMARY GLAND BIOL & NEOPLASIA. Neville MC and Medina D, Eds. 3(1), 1998

Horwitz KB (Editor). Progesterone and Progesterone Receptors in Breast Cancer. IN: BREAST CANCER RESEARCH AND TREATMENT. 2002.

BOOK CHAPTERS AND REVIEWS

1. **Horwitz Kathryn Bloch.** The In Vitro Culture of Embryos of the Viviparous Teleost *Xiphophorus maculatus*, (Thesis for Master of Science in Biology), New York University, 1966.
2. **Horwitz KB.** Progesterone Receptors and Hormone Dependent Breast Cancer (Doctoral Dissertation), The University of Texas Health Science Center, Dallas, Texas, 1975.
3. McGuire WL and **Horwitz KB.** Hormone responses and endocrine therapy IN: INSERM symp. "Hormone Receptors and Endocrine Therapy in Human Breast Cancer" INSERM, Paris, Vol. 55:39-44, 1975.
4. McGuire WL, Chamness GC, Costlow ME and **Horwitz KB.** Hormone receptors in breast cancer. IN: MODERN PHARMACOLOGY, GS Levey (ed.), Marcel Dekker, Inc., New York, pp 265-299, 1976.
5. McGuire WL, **Horwitz KB** and De La Graza M. A biochemical basis for selecting endocrine therapy in human breast cancer. IN: BREAST CANCER: TRENDS IN RESEARCH AND TREATMENT. JC Heuson, WH Mattheiem and M Rozencweig (eds.), Raven Press, New York, pp 177-182, 1976.
6. McGuire WL, **Horwitz KB** and De La Garza M. Selecting endocrine therapy in breast cancer. IN: STEROID HORMONE ACTION AND CANCER. KMJ Menon and Jerry R Reel (eds.), Plenum Pub. Corp., New York, p 28, 1976.
7. McGuire WL and **Horwitz KB.** A role for progesterone in breast cancer. ANNALS NY ACAD SCI 286:90-100, 1977.
8. McGuire WL, Chamness GC, **Horwitz KB** and Zava DT. Prolactin and estrogen receptors. IN: PATHOBIOLOGY ANNUAL 1977. HL Joachim (ed.), Appleton-Century-Crofts, New York, In Press, 1977.

9. **Horwitz KB** and McGuire WL. Estrogen and progesterone: their relationship in hormone dependent breast cancer. IN: PROGESTERONE RECEPTORS IN NORMAL AND NEOPLASTIC TISSUE. WL McGuire, JP Raynaud and EE Baulier (eds.), Raven Press, New York, pp 103-124, 1977.
10. McGuire WL, Zava DT, **Horwitz KB** and Chamness GC. Steroid receptors in breast tumors - current status. IN: CURRENT TOPICS IN EXPERIMENTAL ENDOCRINOLOGY. L Martini and VHT James (eds.), Academic Press, New York, pp 129-189, 1978.
11. McGuire WL, Zava DT, **Horwitz KB** and Chamness GC. Hormones, Receptors and Breast Cancer. IN: TUMOR MARKERS, DETERMINATION AND CLINICAL ROLE - VIth TENOVS WORKSHOP. K Griffiths (ed.), Alpha Omega Alpha Publishing, Cardiff, Wales, pp 153-161, 1978.
12. McGuire WL, Chamness GC, **Horwitz KB** and Zava D. Hormones and their receptors in breast cancer. IN: HORMONE RECEPTORS, VOLUME 1: STEROID HORMONES. Bert O'Malley and Lutz Birnbaumer (eds.), Academic Press, New York, pp 401-441, 1977.
13. McGuire WL and **Horwitz KB**. Steroid hormone receptors in breast cancer. PROCEEDINGS, FIFTH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY. Hamburg, July 1976, Vol. 2 (ed.) VH James, Excerpta Medica, Amsterdam, pp 405-409, 1977.
14. McGuire WL, Zava DT, **Horwitz KB** and Chamness GC. Selecting breast cancer patients for endocrine therapy. IN: HORMONE DEPRIVATION IN BREAST CANCER. M Mayer, S Saez and B Stoll (eds.), ICI Press, pp 1-12, 1978.
15. McGuire WL, Zava DT, **Horwitz KB**, Garola RE and Chamness GC. Steroid hormone receptors in breast cancer. IN: ONTOGENY OF RECEPTORS AND MODE OF ACTION OF REPRODUCTIVE HORMONES. TH Hamilton, JH Clark and W Sadler (eds.), Raven Press, 1978.
16. McGuire WL, **Horwitz KB**, Zava DT, Garola RE and Chamness GC. Hormones in breast cancer - update 1978. METABOLISM 27:487-501, 1978.
17. **Horwitz KB** and McGuire WL. Antiestrogens in breast cancer. IN: BREAST CANCER: MODERN APPROACHES TO THERAPY AND RESEARCH, Vol II, WL McGuire (ed.), Plenum Press, New York, pp 155-204, 1978.
18. McGuire WL, **Horwitz KB**, Zava DT and Garola RE. Estrogen and progesterone receptors in human breast cancer. IN: STEROID RECEPTORS AND THE MANAGEMENT OF CANCER. EB Thompson and M Lippman (eds.), CRC Press, Cleveland, pp 31-40, 1979.

19. McGuire WL, **Horwitz KB**, Zava DT and Garola RE. Interpreting data from steroid receptor assays in human breast tumor tissue. *REVIEWS ON ENDOCRINE-RELATED CANCER*. B Stoll (ed.), ICI Press, pp 5-11, 1978.
20. McGuire WL and **Horwitz KB**. Progesterone receptors in breast cancer. IN: *HORMONES, RECEPTORS AND BREAST CANCER*. WL McGuire (ed.), Raven Press, New York, pp 31-42, 1978.
21. **Horwitz KB** and McGuire WL. Estrogen and antiestrogen action in human breast cancer: Role of nuclear estrogen receptor processing. IN *BREAST CANCER: NEW CONCEPTS IN: ETIOLOGY AND CONTROL*. MJ Brennan, GM McGrath and MA Rich (eds.), Academic Press, New York, pp 89-108, 1980.
22. McGuire WL and **Horwitz KB**. Action of estrogen and antiestrogen in human breast cancer cells. *COLD SPRING HARBOR SYMPOSIUM, VOL. 6, HORMONES AND CELL CULTURE*, pp 937-947, 1980.
23. **Horwitz KB**. Antiestrogens and human breast cancer: Effects and mechanisms of action. IN: K Fothersby and SB Pal (eds.), *HORMONES IN NORMAL AND ABNORMAL HUMAN TISSUES*. Walter de Gruyter & Co., Berlin/New York, pp 81-113, 1981.
24. Mockus MB and **Horwitz KB**. Pregnancy, lactation and breast cancer. IN: *THE PHYSIOLOGICAL BASIS OF LACTATION AND BREAST-FEEDING*. M Neville and M Neifert (eds.), Plenum Press, New York, pp 423-439, 1983.
25. **Horwitz KB**, Wei LL, Sedlacek SM and d'Arville CN. Progestin action and progesterone receptor structure in human breast cancer: A review. *REC PROG HORMONE RES*, 41:249-316, 1985.
26. **Horwitz KB**, Sedlacek SM, d'Arville CN and Wei LL. Progestin treatment, progesterone receptors and breast cancer. IN: *MOLECULAR MECHANISMS OF STEROID HORMONE ACTION*. VK Mougdil (ed.), Walter de Gruyter, New York, pp 659-700, 1985.
27. Wei LL and **Horwitz KB**. The structure of progesterone receptors. *STEROIDS*, pp 677-695, 1985.
28. **Horwitz KB**, Francis MD and Wei LL. Human breast cancer progesterone receptors have two intracellular hormone binding proteins that are covalently modified in nuclei. IN: *GENE REGULATION BY STEROID HORMONES, III*, AK Roy and JH Clark (eds.), Springer-Verlag, pp 66-84, 1986.
29. **Horwitz KB**. The structure and function of progesterone receptors in breast cancer. *J STEROID BIOCHEM*, 27:447-457, 1987.

30. **Horwitz KB** and Francis MD. Chapter 4. Techniques in affinity labeling progesterone receptors; and Chapter 11. Photoaffinity labeling of human progesterone receptors. IN: AFFINITY LABELING AND CLONING OF STEROID AND THYROID HORMONE RECEPTORS, H Gronemeyer (ed.), Ellis Horwood, Ltd., Chichester pp 68-75 and pp 186-198, 1988.
31. Krett NL, Edwards DP and **Horwitz KB**. Progesterone action and receptors. IN: HORMONES AND THEIR ACTIONS, PART I, BA Cooke, RJB King, and HJ van der Molen (eds.), Elsevier Science Publishers by Amsterdam, 241-267, 1988.
32. **Horwitz KB**. Human progesterone receptors A and B: Two independent, functional forms. IN: MEADOW BROOK CONFERENCE ON STEROID RECEPTORS IN HEALTH AND DISEASE, VK Moudgil and JT Posillico (eds.), Plenum Publishing Corp., pp 111-118, 1988.
33. **Horwitz KB**. The central role of progesterone receptors and progestational agents in the management and treatment of breast cancers. IN: ADVANCES IN THE MANAGEMENT OF HORMONE RESPONSIVE DISEASES, CK Osborne (ed.), Seminars in Oncology 15(2):14-19, 1988.
34. **Horwitz KB**, Graham ML, and Jewett PB. The future of flow cytometry: Can a single assay, using small cell numbers, measure all prognostic markers in breast cancer? IN: BIOLOGICAL MODULATORS AND CLINICAL RESPONSE IN ONCOLOGY, A Manni, F Pannuti, G Robustelli della Anna (eds.), Edizione Medico Scientifiche-Pavia, p 157, 1991.
35. **Horwitz KB**. Cellular heterogeneity and mutant estrogen receptors in breast cancer. IN: CANCER SURVEYS Volume 14: GROWTH REGULATION BY NUCLEAR HORMONE RECEPTORS. MG Parker (ed.), Cold Spring Harbor Laboratory Press, New York, pp 41-54, 1992.
36. **Horwitz KB**. Can hormone "resistant" breast cancer cells be inappropriately stimulated by tamoxifen? ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 684:63-74, 1993.
37. **Horwitz KB**. Hormone "resistance" in breast cancer: The role of normal and mutant receptors. IN: MAMMARY TUMORIGENESIS AND MALIGNANT PROGRESSION. ME Lippman and RB Dickson (eds.), Kluwer Academic Publishers, Boston/Dordrecht/London, p 111, 1994.
38. **Horwitz KB**. Hormone resistant breast cancer -- or -- "Feeding the hand that bites you". IN: RECEPTOR MEDIATED BIOLOGICAL PROCESSES: IMPLICATION FOR EVALUATING CARCINOGENESIS. HL Spitzer *et al* (ed.), Wiley-Liss Publishers, p 29-46, 1994.

39. Groshong SD and **Horwitz KB**. A dual parameter flow cytometry assay for progesterone receptors and DNA indices. IN: RECEPTOR RESEARCH METHODS. BD Greenstein (ed.), Horwood Academic Publishers, Philadelphia, pp. 211-232, 1995.
40. **Horwitz KB**. Antiprogestins and the treatment of breast cancer. IN: CLINICAL APPLICATIONS OF MIFEPRISTONE AND OTHER ANTIPROGESTINS. NATIONAL ACADEMY PRESS, MS Donaldson, L Dorflinger, SS Brown and LZ Benet (eds.), Washington, DC, pp. 210-228, 1993.
41. **Horwitz KB**, Sartorius CA, Hovland AR, Jackson TA, Groshong SD, Tung L and Takimoto GS. Surprises with antiprogestins: Novel mechanisms of progesterone receptor action. IN: NONREPRODUCTIVE ACTIONS OF SEX STEROIDS, E-E Baulieu (ed.), Ciba Foundation Symposium 191, John Wiley & Sons, Inc., NY, pp. 235-253, 1995.
42. **Horwitz KB**. How do breast cancers become hormone resistant? J STEROID BIOCHEM MOLEC BIOL, 49:295-302, 1994.
43. **Horwitz KB**, Sartorius CA, Hovland AR, Jackson TA, Groshong SD, Tung L and Takimoto GS. Novel mechanisms of progesterone receptor action: Surprises with antiprogestins. IN: J STEROID BIOCHEM MOLEC BIOL, Vol. 53, pp. 9-17, 1994.
44. **Horwitz KB**, Tung L and Takimoto GS. Novel mechanisms of antiprogestin action. Plenary Lecture, IN: IX INTERNATIONAL CONGRESS OF HORMONAL STEROIDS, In Press, 1995.
45. **Horwitz KB**, Tung L and Takimoto GS. Progestins, progesterone receptors and breast cancer. IN: HORMONES AND CANCER, WV Vedeckis (ed.), Birkhäuser Press, pp 283-306, 1996.
46. **Horwitz KB**, Tung L and Takimoto GS. Novel mechanisms of antiprogestin actions: tissue specificity and hormone resistance. ACTA ONCOLOGICA 35(2):129-140, 1996.
47. **Horwitz KB**, Tung L and Takimoto GS. Why are there two progesterone receptors? THE BREAST, 5:216-223, 1996.
48. Leslie KK, Kumar NS, Richer J, Owen G, Takimoto GS, **Horwitz KB** and Lange C. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells: Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. ANN NY ACAD SCI 828:17-26, 1997

49. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L and **Horwitz KB**. Nuclear receptor conformation, coregulators and tamoxifen resistant breast cancer. *STEROIDS*, 65(10-11): 579-584, 2000.
50. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L and **Horwitz KB**. Thoughts on Tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? *J STEROID BIOCHEM*. 74(5): 255-259, 2000.
51. Richer JK, Jacobsen BM, Sartorius CA and **Horwitz KB**. Expression profiling of human breast cancers and gene regulation by progesterone receptors. *JOURNAL OF MAMMARY GLAND BIOLOGY & NEOPLASIA*, 8(3): 257-268, 2003.
52. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, **Horwitz, KB** and Jacobsen BM. Progesterone Receptor Action: Translating Studies in Breast Cancer Models to Clinical Insights. *Innovative Endocrinology of Cancer*, Bernstein LM and Santen RJ, editors, Landes Bioscience, 2007; *ADV EXP MED BIOL* 630:94-111, 2008

ABSTRACTS PRESENTED AT NATIONAL / INTERNATIONAL MEETINGS

1. **Horwitz KB** and McGuire WL. Specific progesterone receptors in human breast cancer. AMERICAN SOC FOR CLIN INVEST (SOUTHERN), JAN 1975; AMER SOC FOR CLIN RES (NATIONAL), MAY 1975.
2. **Horwitz KB** and McGuire WL. Progesterone receptors in mammary carcinoma. ROUSSEL WORKSHOP, MONTREAL, OCTOBER 1976.
3. **Horwitz KB** and McGuire WL. Progesterone and progesterone receptors in experimental breast cancer. AM SOC FOR CLIN RES (SOUTHERN), JAN 1977.
4. **Horwitz KB** and McGuire WL. Induction of progesterone receptor in a human breast cancer cell line. AM SOC FOR CLIN RES (NATIONAL), MAY 1977.
5. **Horwitz KB** and McGuire WL. Mechanism of estrogen and antiestrogen action in human breast cancer: Role of nuclear processing of estrogen receptor. AM SOC FOR CLIN INVEST (NATIONAL), MAY 1978.
6. **Horwitz KB** and McGuire WL. Nuclear processing of estrogen receptor: Inhibition by Actinomycin D. THE ENDOCRINE SOCIETY, JUNE 1978.
7. **Horwitz KB**, Archuleta JM and Horwitz LD. Vascular tissues are targets for estrogens, androgens and glucocorticoids. AM SOC FOR CLIN RES (WESTERN), FEBRUARY 1981; (NATIONAL), MAY 1981.
8. Mockus MB, Lessey BA, Bower MA and **Horwitz KB**. Apparent estrogen-insensitive human breast cancer cell line: Stoichiometry of nuclear progesterone receptor action. THE ENDOCRINE SOCIETY, JUNE 1981.
9. **Horwitz KB**. Are functional estrogen receptors required for progesterone receptor induction in breast cancer? 5th INTERNATIONAL SYMPOSIUM OF THE JOURNAL OF STEROID BIOCHEMISTRY, PUERTO VALLARTA, MEXICO, JULY 1981.
10. Lessey BA and **Horwitz KB**. The human progesterone receptor consists of dissimilar subunits: Characterization by chromatography and photoaffinity labeling. THE ENDOCRINE SOCIETY, JUNE 1982.
11. Mockus MB and **Horwitz KB**. Progesterone receptors in human breast cancer cells: Translocation, processing and replenishment. THE ENDOCRINE SOCIETY, JUNE 1982.
12. **Horwitz KB**. Variant human breast cancer cells that synthesize large amounts of progesterone receptors despite estrogen and antiestrogen resistance. UCLA

- SYMPOSIA ON EVOLUTION OF HORMONE RECEPTOR SYSTEMS; and GENE REGULATION, J OF CELL BIOCH, Abstracts 447 and 972.
13. Pike AW, Klein J, Fennessey PV and **Horwitz KB**. Applications of steroid profiling in clinical medicine. THE AMER SOC OF MASS SPECTROMETRY, MAY 1983.
 14. **Horwitz KB**, Freidenberg GR, Sheridan RL and Alexander PS. Progestins and the antiprogestin RU38 486: Effects on progesterone receptors and on proliferation of human breast cancer cells. THE ENDOCRINE SOCIETY, MAY 1983.
 15. **Horwitz KB**. Progestins, antiprogestins and progesterone receptors in breast cancer: Mechanisms and biological actions. SECOND INTERNATIONAL CONGRESS ON HORMONES AND CANCER, SEPTEMBER 1983.
 16. Fennessey PV, Pike AW and **Horwitz KB**. The metabolism of progesterone in human breast cancer. INTERNATIONAL SYMPOSIUM ON MASS SPECTROMETRY IN THE HEALTH AND LIFE SCIENCES, SAN FRANCISCO, SEPTEMBER 1984.
 17. **Horwitz KB**. Changes in steroid receptors after hormone binding. UPDATE ON STEROID RECEPTORS IN BREAST CANCER: NEW CONCEPTS AND TECHNIQUES, QUEBEC CITY, SEPTEMBER 1984.
 18. **Horwitz KB**. Structural analyses of human progesterone receptors. 7th INTERNATIONAL SYMPOSIUM OF THE JOURNAL OF STEROID BIOCHEMISTRY, AUSTRIA, JUNE 1985.
 19. **Horwitz KB**, Francis MD and Wei LL. Structural analyses of the human breast cancer progesterone receptor. THE ENDOCRINE SOCIETY, JUNE 1985.
 20. **Horwitz KB**. The structure and function of progesterone receptors in breast cancer. THIRD MEADOW BROOK CONFERENCE ON THE MOLECULAR MECHANISMS OF STEROID HORMONE ACTION, ROCHESTER, MI, SEPTEMBER 1985.
 21. Hiatt WR, Travis VL, **Horwitz KB** and Horwitz LD. The effect of platelet protein and DNA on the measurement of human lymphocyte beta adrenergic receptor number. AMERICAN HEART ASSOCIATION, NOVEMBER 1985.
 22. Wei LL, Suba EJ, Sheridan PL, Francis MD, Edwards DP and **Horwitz KB**. Immunologic analysis of the nuclear modifications and processing of human breast cancer progesterone receptors. THE ENDOCRINE SOCIETY, JUNE 1986.

23. Suba EJ, Estes PA, Wei LL, **Horwitz KB** and Edwards DP. Immunoaffinity purification and structural analysis of the progesterone receptors from human breast cancer cells. THE ENDOCRINE SOCIETY, JUNE 1986.
24. **Horwitz KB**. The molecular biology of progesterone in breast cancer. VII INTERNATIONAL CONGRESS ON HORMONAL STEROIDS, MADRID, SPAIN, SEPTEMBER 1986.
25. Sheridan PL, Krett NL and **Horwitz KB**. In vivo phosphorylation of human breast cancer progesterone receptors. THE ENDOCRINE SOCIETY, JUNE 1987.
26. Wei LL, Krett NL, Gordon DF, Wood WM and **Horwitz KB**. Regulation of progesterone receptor mRNA in human breast cancer cells. THE ENDOCRINE SOCIETY, JUNE 1987.
27. Graham ML, Bunn PA and **Horwitz KB**. Flow cytometry analysis of progesterone receptors and tumor cell proliferation in breast cancer. AMERICAN SOCIETY FOR CLINICAL RESEARCH (WESTERN), FEBRUARY 1988.
28. Graham ML, Bunn PA, Jewett PB and **Horwitz KB**. Simultaneous flow cytometry measurement of progesterone receptors (PR) and DNA indices in breast cancer. AMERICAN FEDERATION FOR CLINICAL RESEARCH, MAY 1988.
29. Sheridan PL, Evans RM and **Horwitz KB**. Analysis of human progesterone receptor synthesis, phosphorylation and processing. THE ENDOCRINE SOCIETY, JUNE 1988.
30. Krett NL, Wei LL, Nordeen SK, Miller LA, Wood WM, Gordon DF and **Horwitz KB**. Human progesterone A-receptors are synthesized intracellularly and are biologically functional. THE ENDOCRINE SOCIETY, JUNE 1988.
31. Graham ML, Bunn PA and **Horwitz KB**. Simultaneous flow cytometry (FCM) measurement of progesterone receptors (PR) and DNA indices in breast cancer cell lines. SAN ANTONIO BREAST CANCER SYMPOSIUM, NOVEMBER 1988.
32. Krett NL, Miller LA, Francis MD, Leslie KK, Wei LL and **Horwitz KB**. Estrogen resistance in T47Dco cells may result from a mutant estrogen receptor. THE ENDOCRINE SOCIETY, JUNE 1989.
33. Graham ML, Miller LA, Krett NL, Francis MD and **Horwitz KB**. Genetic instability and mutant estrogen receptors in the T47D breast cancer cell line: A model for progression to hormone resistance. SAN ANTONIO BREAST CANCER SYMPOSIUM, DECEMBER 1989.

34. **Horwitz KB**, Graham II ML and Miller LA. Hormone resistant breast cancer: Genetic instability and mutant estrogen receptors. AMERICAN ASSOCIATION FOR CANCER RESEARCH, MAY 1990.
35. Graham II ML, Smith JA, Jewett PB and **Horwitz KB**. A quantitative flow cytometry immunoassay for DNA indices and intranuclear proteins. AMERICAN ASSOCIATION FOR CANCER RESEARCH, MAY 1990.
36. Wei LL, Gonzalez-Aller C and **Horwitz KB**. Oligonucleotide mapping of the multiple human progesterone receptor messages. THE ENDOCRINE SOCIETY, JUNE 1989.
37. Miller LA, Leslie KK, Graham II ML, Francis MD and **Horwitz KB**. Hormone resistant breast cancer is linked to genetic instability and mutant estrogen receptors. THE ENDOCRINE SOCIETY, JUNE 1990.
38. Leslie KK, Miller LA, Gramham ML and **Horwitz KB**. Mutant estrogen receptors: A mechanism for estrogen resistance? FIRST CONFERENCE PRIMATE ENDOMETRIUM, MAY 28-30, 1990.
39. **Horwitz KB**. A quantitative flow cytometry immunoassay for DNA indices and progesterone receptors. 15TH INTERNATIONAL CANCER CONGRESS, AUGUST, 1990.
40. **Horwitz KB**. Hormone resistant breast cancer: genetic instability and mutant receptors, 15TH INTERNATIONAL CANCER CONGRESS, AUGUST, 1990.
41. Graham, ML, Smith J and **Horwitz KB**. A quantitative flow cytometric assay to measure intracellular or extracellular epitopes of the surface protein product of the *her2/heu* oncogene. SAN ANTONIO BREAST CANCER SYMPOSIUM. NOVEMBER, 1990.
42. Crowley ST, **Horwitz KB** and Horwitz LD. Other platelet products synergize with platelet derived growth factor to stimulate vascular smooth muscle cell proliferation. AMERICAN ASSOCIATION FOR CLINICAL RESEARCH, MAY, 1991.
43. Takimoto GS, Tasset DM, Eppert AC and **Horwitz KB**. Transcription is regulated by phosphorylation of human progesterone receptors following DNA binding. THE ENDOCRINE SOCIETY, JUNE, 1991.
44. Leslie KK and **Horwitz KB**. Functional analysis of a mutant estrogen receptor isolated from T47D_{CO} breast cancer cells. THE AMERICAN ASSOCIATION OF OBSTETRICS AND GYNECOLOGY, SEPTEMBER, 1991.

45. **Horwitz KB**, Takimoto GS, Tung L and Sartorius CA. Regulation of human progesterone receptors by phosphorylation. KEYSTONE SYMPOSIUM ON STEROID/THYROID RECEPTOR GENE SUPERFAMILY, FEBRUARY, 1992.
46. Leslie KK and **Horwitz KB**. Functional analysis of mutant estrogen receptors, and cellular heterogeneity in T47D_{CO} breast cancer cells. KEYSTONE SYMPOSIUM ON STEROID/THYROID RECEPTOR GENE SUPERFAMILY, FEBRUARY, 1992.
47. Sartorius CA, Takimoto GS, Tung L and **Horwitz KB**. Progesterone receptor phosphorylation: Regulation by cAMP and by the progesterone antagonist ZK98299. THE ENDOCRINE SOCIETY, JUNE, 1992.
48. **Horwitz KB**. Hormone resistant breast cancer: Genetic instability, subcellular heterogeneity and mutant steroid receptors. COLD SPRING HARBOR LABORATORY: GENETICS AND MOLECULAR BIOLOGY OF BREAST CANCER, SEPTEMBER, 1992.
49. **Horwitz KB**. Estrogen receptor mutants and cellular heterogeneity in hormone resistant breast cancer. IX INTERNATIONAL CONGRESS ON ENDOCRINOLOGY: SATELLITE SYMPOSIUM: ZINC FINGER PROTEINS IN ONCOGENESIS, DNA-BINDING AND GENE REGULATION. AMSTERDAM, SEPTEMBER, 1992.
50. Crowley ST, Dempsey EC, **Horwitz KB** and Horwitz LD. Platelet induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. 66th Meeting, AMERICAN HEART ASSOCIATION, NOVEMBER, 1993.
51. **Horwitz KB**. How do breast cancers become hormone resistant? The Rhone-Poulenc Rorer Clinical Lecture, THE ENDOCRINE SOCIETY, Las Vegas, June, 1993.
52. Jackson TA, Tung L, Takimoto GS and **Horwitz KB**. Antagonist-occupied human progesterone B-receptors activate transcription without binding to a progesterone response element. THE ENDOCRINE SOCIETY, Las Vegas, June, 1993.
53. **Horwitz KB**. How do breast cancers become hormone resistant? ISGSH XVI MEETING, Vienna, Austria, November, 1993.
54. **Horwitz KB**. Agonist effects of antagonist-occupied progesterone B-receptors: New model systems. KEYSTONE SYMPOSIA, Taos, NM, February, 1994.
55. Groshong SD, Sartorius CA, Powell RL, Miller LA, Jackson TA and **Horwitz KB**. The transcriptional and proliferative effects of progestin agonists, antagonists and cAMP on PR-negative T47D cells stably transfected with either hPRA or hPRB.

56. Sartorius CA, Milville MY, Tung L, Takimoto GS and **Horwitz KB**. A third transactivation function of progesterone receptors unique to the B-isoform.
57. Mohamed MK, Hovland AR, Tung L, Takimoto GS and **Horwitz KB**. The leucine zippers of C-fos and C-jun: A new tool for the formation of pure heterodimers between the two progesterone receptor isoforms.
58. **Horwitz KB**. Antiestrogens, antiprogestins and hormone resistant breast cancer. KEYSTONE SYMPOSIA, Lake Tahoe, CA, March, 1994.
59. **Horwitz KB**. Agonist effects of antagonist-occupied progesterone B-receptors. 21st GERMAN CANCER SOCIETY CONGRESS, Hamburg, Germany, March, 1994.
60. **Horwitz KB**. Symposium Lecture: Abnormal responses to hormones in breast cancer. AMERICAN ASSOCIATION FOR CANCER RESEARCH, San Francisco, CA, April, 1994.
61. **Horwitz KB**. President's Lecture: Reproductive Hormones and Breast Cancer. THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, Chicago, IL, April, 1994.
62. Tung L, Takimoto GS, Sartorius CA, Groshong SD and **Horwitz KB**. Agonist effects of antagonists on progesterone B-receptors: New models of hormone-resistant breast cancer. THE ENDOCRINE SOCIETY, Anaheim, CA, June, 1994.
63. **Horwitz KB**. Ovarian hormones, antagonists and breast cancer. NORTH AMERICAN MENOPAUSE SOCIETY, San Francisco, CA, September, 1995.
64. **Horwitz KB**. Plenary lecture: Unusual actions of antiprogestins. ERNST SCHERING RESEARCH FOUNDATION, Berlin, Germany, November, 1995.
65. **Horwitz KB**, Bain DL, Groshong SD, Hovland AR, Jackson TA, Lange-Carter C, Richer JK, Sartorius CA, Takimoto GS, Tung L and Wierman A. Progesterone receptor isoforms and variants in breast cancer. NUCLEAR RECEPTORS KEYSTONE SYMPOSIUM, Lake Tahoe, California, 1996.
66. Hovland AR, Powell RL, Takimoto GS, Tung L and **Horwitz KB**. A novel N-terminal inhibitory function (IF) and three activation functions (AFs) in human progesterone A- and B-receptors control their transcriptional diversity. NUCLEAR RECEPTORS KEYSTONE SYMPOSIUM, Lake Tahoe, California, 1996.
67. Richer JK, Wierman AM, Lange-Carter C and **Horwitz KB**. Variant progesterone receptors in human breast cancer cell lines and tumors. NUCLEAR RECEPTORS KEYSTONE SYMPOSIUM, Lake Tahoe, California, 1996.

68. Miller MM, Gordon DF, James RA, Wood WM, Richer JK and **Horwitz KB**. Differentially expressed genes under the control of progesterone receptor A- or B-isoforms. NUCLEAR RECEPTORS KEYSTONE SYMPOSIUM, Lake Tahoe, California, 1996.
69. Takimoto GS, Hovland AR, Tung L and **Horwitz KB**. Function of phosphorylation in human progesterone receptors. NUCLEAR RECEPTORS KEYSTONE SYMPOSIUM, Lake Tahoe, California, 1996.
70. Jackson TA, Bain DL and **Horwitz KB**. Antagonist-dependent inhibition by progesterone receptors is mediated by a nuclear repressor. NUCLEAR RECEPTORS KEYSTONE SYMPOSIUM, Lake Tahoe, California, 1996.
71. Groshong SD, Daly MC, Schauer IE, Sclafani RA, Langan TA and **Horwitz KB**. Progesterone regulation of the proliferative cell cycle in T47D breast cancer cells. NUCLEAR RECEPTORS KEYSTONE SYMPOSIUM, Lake Tahoe, California, 1996.
72. Sartorius CA, Takimoto GS, Tung L, **Horwitz KB**. The DNA binding domain of human progesterone receptors recruits a DNA-dependent protein kinase to the transcription complex. THE ENDOCRINE SOCIETY, Minneapolis, Minnesota, June 1997.
73. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, and **Horwitz KB**. The partial agonist activity of antagonist-occupied steroid receptors is controlled by the ratio of coactivators to corepressors recruited to the transcription complex. THE ENDOCRINE SOCIETY, Minneapolis, Minnesota, June 1997.
74. Kumar NS, Owen G, Richer J, Takimoto G, **Horwitz KB** and Leslie KK. Differential expression of the A and B isoforms of progesterone receptor in endometrial cancer cells: Primarily PRB is induced by estrogens and associated with strong transcriptional activation. THE ENDOCRINE SOCIETY, Minneapolis, Minnesota, June 1997.
75. **Horwitz KB**. Hormones, hormone resistance and breast cancer. Plenary Lecture, AUSTRALIAN SOCIETY FOR MEDICAL RESEARCH, Adelaide, November, 1997.
76. **Horwitz KB**, Groshong S and Owen GI. Growth regulation of breast tumor cells by progesterone. Symposium Lecture, AUSTRALIAN SOCIETY FOR MEDICAL RESEARCH, Adelaide, November, 1997.
77. Hodges-Garcia YK, Perryman, MB, **Horwitz KB** and Horwitz LD. Estrogen regulation of an RNA polymerase II subunit in human vascular smooth muscle cells. CIRCULATION 96: (8) 1277 Suppl. S, Oct. 1997

78. Hodges-Garcia YK, Richer JK, Tung L, Graham JD, **Horwitz KB** and Horwitz LD. Structural heterogeneity of estrogen and progesterone receptor expression in human vascular smooth muscle (VSM). Nuclear Receptor Gene Family, KEYSTONE SYMPOSIA, Lake Tahoe, CA, March, 1998.
79. Bain DL, Takimoto GS and **Horwitz KB**. Activation function 3 (AF-3), unique to the B isoform of human progesterone receptors, is natively unfolded. Nuclear Receptor Gene Family, KEYSTONE SYMPOSIA, Lake Tahoe, CA, March, 1998.
80. Bain DL, Takimoto GS and **Horwitz KB**. Activation function 3 (AF-3), unique to the B isoform of human progesterone receptors, is natively unfolded. BIOPHYS. J. 74: (2)A275 part 2, Feb. 1998
81. Lange CA, Miller KM, Richer JK and **Horwitz KB**. Cross-talk between progesterone and type I growth factor receptors regulates breast cancer cell growth. Nuclear Receptor Gene Family, KEYSTONE SYMPOSIA, Lake Tahoe, CA, March, 1998.
82. Graham JD, Tung L, Osborne CK, Fuqua SAW and **Horwitz KB**. Quantitative analysis of nuclear coregulators in breast cancer. Nuclear Receptor Gene Family, KEYSTONE SYMPOSIA, Lake Tahoe, CA, March, 1998.
83. Owen GI, Richer JK, Tung L, Takimoto G and **Horwitz KB**. Progesterone regulates transcription of the p21^{WAF1} cyclin-dependent-kinase inhibitor gene through Sp1 and CBP/p300. Nuclear Receptor Gene Family, KEYSTONE SYMPOSIA, Lake Tahoe, CA, March, 1998.
84. Richer JK and **Horwitz KB**. Regulation of Stat 5a and 5b by progestins in breast cancer cells and their interaction with progesterone receptors. Nuclear Receptor Gene Family, KEYSTONE SYMPOSIA, Lake Tahoe, CA, March, 1998.
85. **Horwitz KB**, Owen GI, Richer JK, Lange C, Tung L and Takimoto G. Breast cancer growth regulation by progesterone and cross-talk with epidermal growth factor. Symposium Lecture, Nuclear Receptor Gene Family, KEYSTONE SYMPOSIA, Lake Tahoe, CA, March, 1998.
86. Graham JD, Tung L, Osborne CK, Fuqua SAW and **Horwitz KB**. Quantitative analysis of nuclear receptor coregulators and hormone resistant breast cancer. 80th Annual Meeting, THE ENDOCRINE SOCIETY, June 24-27, 1998. Abst # OR40-1.
85. Richer JK, Lange CA, Manning NG, Powell RL and **Horwitz KB**. Convergence of progesterone and epidermal growth factor signaling: Receptors interact with STAT5 and induce their nuclear translocation. 80th Annual Meeting, THE ENDOCRINE SOCIETY, June 24-27, 1998, Abst # OR48-4.

86. Lange CA, Miller KM, Richer JK and **Horwitz KB**. Cross-talk between progesterone and Type I growth factor receptors regulates breast cancer growth. 80th Annual Meeting, THE ENDOCRINE SOCIETY, June 24-27, 1998, Abst # OR49-2.
87. Kumar NS, Litman ES, **Horwitz KB** and Leslie KK. Estrogen and progesterone receptors A and B in endometrial cancer cells: A subpopulation of ER-positive, PR-negative cells is present that may result in hormonal treatment failure. 80th Annual Meeting. THE ENDOCRINE SOCIETY, June 24-27, 1998, Abst # P1-3.
88. Bain DL, Franden MA, Takimoto GS and **Horwitz KB**. Structural analysis of the progesterone receptor A N-terminus. Redefinition of functional domains based on novel structural regions. THE BIOPHYSICAL JOURNAL 74 (2) A275 part 2, 1998
89. Bain DL, Franden MA, Takimoto GS and **Horwitz KB**. Spectroscopic and proteolytic characterization of the human A- and B-progesterone receptor N-terminal regulatory domains. SYMPOSIUM ON THE STEROID RECEPTOR SUPERFAMILY. The American Association of Cancer Research. San Diego, CA Jan. 8-11, 1999.
90. Richer JK, Graham JD and **Horwitz KB**. The A- and B-isoforms of progesterone receptors determine how progesterone can regulate both proliferative and differentiative programs. THE ENDOCRINE SOCIETY, June 12, 1999.
91. Graham JD, Tung L, Fuqua SAW, Osborne CK and **Horwitz KB**. Do transcriptional corepressors control tamoxifen resistance in breast cancer? THE ENDOCRINE SOCIETY, June 12, 1999.
92. Bain DL, Franden MA, Takimoto GS and **Horwitz KB**. Structural analysis of the two human progesterone receptor N-termini explain their isoform-specific functional differences. THE ENDOCRINE SOCIETY, June 12, 1999.
93. Lange CA, Shen T and **Horwitz KB**. Progesterone receptor ubiquitination and ligand-dependent downregulation is due to MAPK phosphorylation of serine 294. THE ENDOCRINE SOCIETY, June 12, 1999.
94. **Horwitz KB**. Growth regulation and steroid hormone resistance in breast cancer. Estrogens and Women's Health. THE NOBEL FOUNDATION, Sweden, June 29, 1999.
95. **Horwitz KB**. The structure and function of progesterone receptor N-termini. PROGESTERONE, PROGESTINS & ANTIPROGESTINS IN THE NEXT MILLENNIUM, Jerusalem, Israel. September 1, 1999.

96. **Horwitz KB.** Insights into tamoxifen resistant breast cancer. SIXTH INT. CONGRESS ON HORMONES & CANCER. Jerusalem, Israel. September 6, 1999.
97. **Horwitz KB.** The role of receptor coactivators and corepressors in tamoxifen-resistant breast cancer. SERMs IMPLICATION FOR PREVENTION AND TREATMENT OF BREAST CANCER. The ER/Breast Cancer Working Group. Philadelphia, PA, November 3, 1999.
98. **Horwitz KB,** Bain DL, Franden MA, Takimoto GS, Richer JK, Lange CA, Manning NA and Jacobsen BM. Structure and function of the N-terminal regions of progesterone receptors. KEYSTONE SYMPOSIA, NUCLEAR RECEPTORS 2000, Steamboat Springs, CO, March 25, 2000.
99. **Horwitz KB.** Control of breast cancer growth by progesterone. Cross-talk with growth factor signaling. HORMONAL CARCINOGENESIS, St. Petersburg, Russia, May 15, 2000.
100. **Horwitz, KB.** Antiestrogen resistance in breast cancer. SIXTH ANNUAL MEDICINE IN THE 21st CENTURY SYMPOSIUM. New Jersey Medical School, Newark, NJ, May 8, 2000.
101. Richer JR, Jacobsen BM, Manning NA, Wolf DM and **Horwitz KB.** The two progesterone receptor isoforms, PR-A and PR-B, regulate genes in opposite directions. THE ENDOCRINE SOCIETY, Toronto, CAN, June 21, 2000.
102. Lange CA, Shen T and **Horwitz KB.** Phosphorylation of human progesterone receptors by MAPKs mediates transcriptional synergy between progestins and MEKK1 in human breast cancer cells. THE ENDOCRINE SOCIETY, Toronto, CAN, June 21, 2000.
103. Tung L, Powell R, Abel MG, Shen T, Sartorius CA and **Horwitz KB.** Defining the mechanism of activation function 3 of human progesterone receptors. KEYSTONE SYMPOSIA, NUCLEAR RECEPTORS 2000. Steamboat Springs, CO, March 25, 2000.
104. Lange CA, Shen T and **Horwitz KB.** Phosphorylation of human progesterone receptors by MAPKs mediates transcriptional synergy between progestins and growth factor signaling in breast cancer. KEYSTONE SYMPOSIA, SIGNALING 2000. January 27, 2000, Keystone, CO.
105. Graham JD, Abel MG, Jackson TA, Gordon DF, Wood WM and **Horwitz KB.** Novel interactors mediating mixed antagonist action on estrogen and progesterone receptors in breast cancer. KEYSTONE SYMPOSIA, NUCLEAR RECEPTORS 2000. Steamboat Springs, CO. March 25, 2000.

106. Richer JR, Jacobsen BM, Manning NA, Wolf DM and **Horwitz KB**. The two progesterone receptor isoforms, PR-A and PR-B, regulate genes in opposite directions. KEYSTONE SYMPOSIA, NUCLEAR RECEPTORS 2000, Steamboat Springs, CO, March 25, 2000.
107. Abdel-Hafiz H, Tung L and **Horwitz KB**. A molecular dissection of the inhibitory function of progesterone receptors. KEYSTONE SYMPOSIA, NUCLEAR RECEPTORS 2000, Steamboat Springs, CO, March 25, 2000.
108. **Horwitz KB**. Growth regulation and steroid hormone resistance in breast cancer. SECOND INT. SYMPOS. on the MOLECULAR BIOLOGY OF BREAST CANCER. Lillehammer, Norway, March 12, 2000.
109. **Horwitz KB**. Estrogen, progesterone and breast cancer growth. Society for Women's Health Research, FIRST CONF. ON SEX AND GENE EXPRESSION. Winston Salem, NC, March 2, 2000.
110. **Horwitz KB**. Structure and function of progesterone receptor N-termini. 14th INT SYMPOS. REC. ADV. IN STEROID REC. BIOCHEM & MOLEC. BIOL. Quebec, CAN, 24 June, 2000.
111. Bain DL, Franden MA, Takimoto GS, McManaman J and **Horwitz KB**. Structural analysis of the N-terminus of PR-A. NUCLEAR RECEPTOR 2000, Steamboat Springs, CO, March 25, 2000.
112. Pahl PMB, Powell R, Horwitz MA, **Horwitz KB** and Horwitz LD. A novel lipophilic iron chelator induces apoptosis in cultured breast cancer cells but does not injure normal mammary epithelial cells. 91st ANNUAL MEETING. THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. San Francisco, CA. April 1-5, 2000. Abstract number 4889.
113. Lange CA, Qiu M, Shen T and **Horwitz KB**. Phosphorylation of human progesterone receptors Ser294 by MAPK couples ligand-dependent degradation, transcriptional synergy and nuclear association. 83rd ANNUAL MEETING OF THE ENDOCRINE SOCIETY. Denver, CO. June 20-23, 2001.
114. Jacobsen BM, Schittone SA, Richer JK and **Horwitz KB**. New human breast cancer cells with inducible progesterone receptors (PR) to study ligand independent and isoform ratio effects. 83rd ANNUAL MEETING OF THE ENDOCRINE SOCIETY. Denver, CO. June 20-23, 2001.
115. Sartorius CA, Shen T and **Horwitz KB**. Human breast cancer cell tumor growth *in vivo*. Influence of Progesterone A- and B-receptors. 83rd ANNUAL MEETING OF THE ENDOCRINE SOCIETY. Denver, CO. June 20-23, 2001.

116. Abel MG, Tung L, Shen T, Sartorius CA, Takimoto GS and **Horwitz KB**. Defining Activation Function 3 (AF3) – A domain unique to the B-isoform of human Progesterone Receptors. 83rd ANNUAL MEETING OF THE ENDOCRINE SOCIETY. Denver, CO. June 20-23, 2001.
117. Richer JK, Jacobsen BM, Manning N and **Horwitz KB**. Two progesterone receptor (PR) isoforms: Differential gene regulation in breast cancer cells. 83rd ANNUAL MEETING OF THE ENDOCRINE SOCIETY. Denver, CO. June 20-23, 2001.
118. Jacobsen BM, Richer JK, Schittone SA and **Horwitz KB**. Ligand independent effects of progesterone receptors (PR) on the array of genes expressed in human breast cancer cells. 84th ANNUAL MEETING OF THE ENDOCRINE SOCIETY. San Francisco, CA June 19-22, 2002.
119. Richer JK, Manning NG and **Horwitz KB**. New transcriptional coregulators of progesterone receptors discovered by cDNA microarray methods. 84th ANNUAL MEETING OF THE ENDOCRINE SOCIETY. San Francisco, CA June 19-22, 2002.
120. Tung L, Abdel-Hafiz H, Abel MG, Shen T, Sartorius CA, Takimoto GS and **Horwitz KB**. Identification of novel N-terminal progesterone receptor regulatory sites and their functional correlations. 84th ANNUAL MEETING OF THE ENDOCRINE SOCIETY. San Francisco, CA June 19-22, 2002.
121. Jacobsen BM, Richer JK, Schittone SA and **Horwitz KB**. New human breast cancer cells with inducible progesterone receptors (PR) to study ligand independent regulation. NUCLEAR RECEPTOR KEYSTONE MEETING, Snowbird, Utah. April 13-19, 2002.
122. Sartorius CA, Shen T and **Horwitz KB**. Role of PR-A and PR-B in estrogen dependent human breast tumor growth. NUCLEAR RECEPTOR KEYSTONE MEETING, Snowbird, Utah. April 13-19, 2002.
123. Abdel-Hafiz H, Tung L, Takimoto GS and **Horwitz KB**. Regulation of the transcriptional activity of progesterone receptors by sumoylation. NUCLEAR RECEPTOR KEYSTONE MEETING, Snowbird, Utah. April 13-19, 2002.
124. Richer JK, Manning NG and **Horwitz, KB**. New transcriptional coregulators of progesterone receptors discovered by cDNA microarray methods. NUCLEAR RECEPTOR KEYSTONE MEETING, Snowbird, Utah. April 13-19, 2002.
125. **Horwitz KB**, Abdel-Hafiz H, Abel MG, Jacobsen BM, Richer JK, Sartorius CA, Takimoto GS and Tung L. N-terminal structure and function in breast cancers of the Progesterone Receptor (PR)-A and PR-B isoforms. NUCLEAR RECEPTOR KEYSTONE MEETING, Snowbird, Utah. April 13-19, 2002.

126. Byron S, **Horwitz KB**, Lange CA, Yee D. Insulin receptor substrate (IRS-1) protein expression requires functional progesterone receptor B in T47D breast cancer cells. AMERICAN ASSOCIATION FOR CANCER RESEARCH, San Francisco, CA, April 1-5, 2002.
127. Hopp TA, Bardou V, Moshin S, Allred DC, Fuqua SAW, **Horwitz KB** and Clark G. Progesterone Receptor B but not A predicts overall survival in tamoxifen treated breast cancer patients. AMERICAN ASSOCIATION FOR CANCER RESEARCH, San Francisco, CA, April 1-5, 2002.
128. **Horwitz KB**. Gene regulation by progesterone receptor isoforms in breast cancer. "Steroid Hormone Receptor Symposium". THE ENDOCRINE SOCIETY, San Francisco, CA, June 20, 2002.
129. **Horwitz KB**. Presidential Lecture. Two progesterone receptors for one hormone. Why? SOCIETY FOR THE STUDY OF REPRODUCTION. Baltimore, MD, July 28-32, 2002.
130. **Horwitz KB**. CME Course, The Endocrine Society. The emerging use of genomics and proteomics in endocrinology. New Orleans, LA, November 14-16, 2002.
131. Abdel-Hafiz H, Takimoto GS, Tung L and **Horwitz KB**. Why are the progesterone receptor B (PR-B) isoforms much stronger transcriptional activators than their PR-A partners? THE ENDOCRINE SOCIETY, Philadelphia, PA, June 19-23, 2003.
132. Harvell DME, Sartorius CA, Richer JK and **Horwitz KB**. Estrogen Regulated Gene Expression is Differentially Modulated by the PR Isoform present in Human Breast Tumor Xenografts. THE ENDOCRINE SOCIETY, Philadelphia, PA, June 19-23, 2003.
133. Jacobsen BM, Schittone SA, Richer JK and **Horwitz KB**. Unliganded Progesterone Receptor A (PR-A) isoforms modify the phenotype of human breast cancer cells. THE ENDOCRINE SOCIETY, Philadelphia, PA, June 19-23, 2003.
134. Wu J, Richer J, **Horwitz KB** and Hyder SM. Progestin dependent induction of VEGF in breast cancer cells: Role of progesterone receptor isoforms. AACR Special Conference on New Directions in Angiogenesis Research. Abstract A19. Chicago, IL, Sept. 2003.
135. Spoelstra NS, Manning NG, Higashi Y, **Horwitz KB**, Richer JK. Progesterone Receptor-mediated regulation of ZEB1 and its role in uterine leiomyomas. KEYSTONE SYMPOSIA ON NUCLEAR RECEPTORS, Keystone, CO, February 26-March 4, 2004

136. Chadli A, Graham JD, Wood WM, Gordon DF, **Horwitz KB** and Toft DO. Characterization of CRIP100: A novel tetratricopeptide repeat protein that interacts with Progesterone Receptors and Hsp90. MOLECULAR CHAPERONES AND HEAT SHOCK RESPONSE, Cold Spring Harbor, NY, May 5-9, 2004
137. Wu J, Richer JK, **Horwitz KB** and Hyder M. Progestin-dependent induction of VEGF in human breast cancer cells: preferential regulation by progesterone receptor-B. AMERICAN ASSOCIATION FOR CANCER RESEARCH, Orlando, FL, May 27-31, 2004
138. Abdel-Hafiz HA, Takimoto GS, Tung L **Horwitz KB**. Sumoylation is a Key Modulator of PR-Coregulator Assembly at Complex Promoters. THE ENDOCRINE SOCIETY, New Orleans, LA, June 16-21, 2004
139. Jacobsen BM, Schittone SA, Richer JK and **Horwitz KB**. Gene regulation by liganded and unliganded human progesterone receptors: progesterone response elements (PRE) are necessary but not sufficient? THE ENDOCRINE SOCIETY, New Orleans, LA, June 16-21, 2004
140. Richer JK, Jacobsen BM, Schittone SA, Manning NG, and **Horwitz KB**. Unique genes are regulated by Progesterone Receptor (PR) AB heterodimers in human breast cancer cells. THE ENDOCRINE SOCIETY, New Orleans, LA, June 16-21, 2004
141. Spoelstra NS, Manning NG, Higashi Y, **Horwitz KB**, Richer JK. Progesterone Receptor-mediated regulation of ZEB1: A mediator of progesterone dependent growth anomalies? THE ENDOCRINE SOCIETY, New Orleans, LA, June 16-21, 2004
142. Sartorius CA, Shen T and **Horwitz KB**. Progestins do not protect against estrogen stimulation in human breast tumor xenografts. THE ENDOCRINE SOCIETY, New Orleans, LA, June 16-21, 2004
143. Harvell DME, Sartorius CA, Richer JK and **Horwitz KB**. Estrogen (E) dependent genes can acquire resistance to long-term E treatments: Implications for hormone resistant breast cancers. THE ENDOCRINE SOCIETY, New Orleans, LA, June 16-21, 2004
144. Bray JD, Jelinsky S, **Horwitz KB** and Lyttle CR. Progesterone Receptor isoform modulation of gene expression in T47D cell lines. THE ENDOCRINE SOCIETY, New Orleans, LA, June 16-21, 2004
145. **Horwitz KB**. Progesterone Receptor biology and therapeutic targeting in breast cancer. FUTURE OF BREAST CANCER, III. INTERNATIONAL BREAST CANCER CONGRESS. Bermuda, July 22-25, 2004.
146. **Horwitz, KB**. Ligand independent regulation of Progesterone Receptor signaling STEROID HORMONE RECEPTORS, FASEB Summer Research Conferences, Tucson, AZ, July 31-August 5, 2004.

147. Harrell JC, Sartorius CA and **Horwitz KB**. A reliable model of estrogen dependent breast cancer lymph node metastasis. SAN ANTONIO BREAST CANCER SYMPOSIUM, December, 2005
148. Richer JK, Harvell DME, Spoelstra N, Singh M, Elias A and **Horwitz KB**. Molecular changes in response to pre-operative endocrine therapy. SAN ANTONIO BREAST CANCER SYMPOSIUM, December 2005
149. Jacobsen BM, Harrell JC, Borges V, Garcia MV and **Horwitz KB**. Spontaneous fusion of mouse stroma with transformed estrogen receptor-positive epithelium in a solid tumor model of human breast cancer. SAN ANTONIO BREAST CANCER SYMPOSIUM, December 2005
150. Harvell DME, Richer JK, Spoelstra N, Singh M, Elias A, Horwitz KB. Estrogen-regulated genes involved in response to neoadjuvant therapy for breast cancer. THE ENDOCRINE SOCIETY, Boston, June 2006
151. Harrell JC and **Horwitz KB**. Characterizing a model of estrogen-dependent breast cancer lymphatic metastasis. Molecular Mechanisms in Lymphatic Function & Disease. GORDON RESEARCH CONFERENCE, Switzerland, September, 2006
152. Christiansen KL, Coletta RD, Jedlicka P, Harrell JC, **Horwitz KB** and Ford HL. Homeoprotein Six 1 induces epithelial to mesenchymal transition and breast cancer metastasis. METASTASIS RESEARCH SOCIETY, Japan, September 2006.
153. Chadli A, Graham JD, Felts SJ, **Horwitz KB**, Toft DO. The role of hsp90 and its co-chaperones in modulating steroid receptor structure and function. NUCLEAR RECEPTORS, Stockholm, Sweden, September 17-20, 2006
154. Harrell JC, Dye WW, Harvell DME, Sartorius CA and **Horwitz KB**. Estrogen regulates different sets of genes in primary breast tumors and their lymph node metastases. KEYSTONE SYMPOSIA: HOST CELL INTERACTION AND RESPONSE TO THE CANCER CELL, January 21, 2007, Keystone, CO
155. Jacobsen BM, Harrell JC, Borges V, Garcia MV and **Horwitz KB**. Spontaneous fusion with, and transformation of host mouse stroma by, malignant human breast cancer epithelium: "cancer within a cancer". DEPARTMENT OF MEDICINE RESEARCH DAY, October 21, 2006, Denver, CO.
156. Gogoi R, Kudla M, Gill O, **Horwitz KB** and Fishman D. An essential role for androgen receptors (AR) in ovarian cancer invasion. SOCIETY FOR GYNECOLOGICAL INVESTIGATION, March 14-17, Reno, NV

157. Christiansen KL, Coletta RD, Jedlicka P, Harrell JC, **Horwitz KB** and Ford HL. The Six 1 homeoprotein plays multiple roles in breast tumorigenesis, promoting transformation, proliferation, survival and metastasis. MOLECULAR TARGETS FOR CANCER, KEYSTONE SYMPOSIA, Whistler, British Columbia, March 18-23, 2007.
158. Abdel-Hafiz H, Perez D and **Horwitz KB**. Modulation of the transcriptional activity of progesterone receptors by the sumoylation pathway. THE UBIQUITIN FAMILY, KEYSTONE SYMPOSIUM, Keystone, CO, April 2007.
159. Harvell DME, Richer JK, Spoelstra NS, Singh M, Finlayson C, Elias AD and **Horwitz KB**. Estrogen regulated gene expression in response to neoadjuvant hormone therapy in breast cancers: Dominance of Tamoxifen agonist effects in the presence of an aromatase inhibitor. 89th ANNUAL MEETING OF THE ENDOCRINE SOCIETY, Oral Session, Toronto, June 5-8, 2007
160. Harvell DME, Spoelstra NS, Singh M, Finlayson C, Elias AD, **Horwitz KB**, Richer JK. Breast cancer androgen receptors are implicated in anti-estrogen failure. 89th ANNUAL MEETING OF THE ENDOCRINE SOCIETY, Poster, Toronto, June 5-8, 2007
161. Sartorius CA, Dye WW, Harrell JC and **Horwitz KB**. Metastasis to boenof ER+ breast cancer cells is estrogen and suppressed by progesterone. 89th ANNUAL MEETING OF THE ENDOCRINE SOCIETY, Poster, Toronto, June 5-8, 2007
162. **Horwitz, KB**. Metastasis models of hormone dependent breast cancer. 6th ANNUAL CONGRESS ON THE FUTURE OF BREAST CANCER, Kohala, Hawaii, July 2007
163. **Horwitz, KB**. Women's hormones and regulation of breast cancer metatasis. ADVANCES IN BREAST CANCER RESEARCH, AACR, October 2007, San Diego, CA
164. **Horwitz, KB**. Metastasis models of hormone dependent breast cancer. 13TH WORLD CONGRESS OF GYNECOLOGICAL ENDOCRINOLOGY, Florence, Italy, February 2008
165. Spillman MA, Sartorius CA, Jacobsen BM, Manning N, Harrell JC and **Horwitz KB**. Estrogen alters tumor growth and metastatic pattern in a human ovarian cancer mouse model. SOCIETY OF GYNECOLOGICAL INVESTIGATION, San Diego, CA, March 25-29, 2008
166. Spillman MA, Sartorius CA, Harrell JC, Manning N, Jacobsen BM and **Horwitz KB**. Estrogen alters tumor growth and metastatic pattern in a human ovarian cancer mouse xenograft model. AMERICAN ASSOCIATION for CANCER RESEARCH, Annual Meeting, San Diego, CA April 12-16, 2008

167. Abdel-Hafiz, HA, Dudevoir ML and **Horwitz KB**. Modulation of the progesterone receptors transcriptional activity by SUMOylation in a promoter-specific manner: Involvement of Steroid Receptor Coactivator 1 (SRC-1). FOURTH INT CONF ON UBIQUITIN, UBIQUITIN-LIKE PROTEINS, AND CANCER, MD ANDERSON, HOUSTON TX, February 7-9, 2008
168. **Horwitz, KB** and Sartorius CA. Hormonal regulation of breast cancer metastasis and breast cancer stem cell. NUCLEAR RECEPTORS, KEYSTONE SYMPOSIA, Whistler, BC, March 30 – April 3, 2008
169. Badtke MM, Jambal P, **Horwitz KB** and Jacobsen BM. Progesterone receptors (PR) modify taxane mediated gene regulation and apoptosis in breast cancer. AMERICAN ASSOCIATION for CANCER RESEARCH, Annual Meeting, San Diego, CA April 12-16, 2008
170. Harvell DME, Richer JK, Spoelstra NS, Singh M, Finlayson C, Elias AD and **Horwitz KB**. Estrogen-regulated gene expression following neoadjuvant hormone therapy of breast cancers: Dominance of tamoxifen agonist effects in the presence of an aromatase inhibitor. AMERICAN ASSOCIATION for CANCER RESEARCH, Annual Meeting, San Diego, CA April 12-16, 2008
171. **Horwitz KB**, Kabos P, Dye WW, Harrell JC, and Sartorius CA. Generation of estrogen and progesterone receptor positive breast cancers from steroid receptor negative cancer stem cells. THE ROLE OF CANCER STEM CELLS IN THE INITIATION AND PROPAGATION OF TUMORIGENESIS. AACR, February 12-15, 2008, Los Angeles, CA
172. Pinto M, Jacobsen BM and Horwitz KB. Malignant stroma enhances proliferation and aggressiveness of breast cancer cells by producing VEGF and TIMP-1. THE ENDOCRINE SOCIETY, ANNUAL MEETING, San Francisco, 2008
173. **Horwitz KB**. The Year in Hormones & Cancer Lecture. THE ENDOCRINE SOCIETY, ANNUAL MEETING, San Francisco, June 2008
174. Harrell JC, Dye WW, Harvell DME, Pinto M, Sartorius CA and **Horwitz KB**. Breast cancer lymphatic dissemination – influence of estrogen and progesterone. Department of Defense Annual Meeting, Washington DC, June 2008

KB Horwitz, Ph.D. Curriculum Vitae

2008CV-KBH